Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CD38 | P28907 | 7/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984117 | 1.00 | KDM4E (0.43) | KDM4EBTKMEN1KMT2AHTR4 | |
| SCHEMBL984754 | 0.94 | HTR4 (0.40) | KDM4EBTKMEN1KMT2AHTR4 | |
| SCHEMBL983455 | 0.92 | KDM4E (0.42) | KDM4EBTKMEN1KMT2AHTR4 | |
| SCHEMBL984888 | 0.92 | KDM4E (0.42) | KDM4EBTKMEN1KMT2AHTR4 | |
| SCHEMBL985809 | 0.92 | HTR4 (0.41) | KDM4EBTKHTR4GRIN1GRIN2B | |
| SCHEMBL981844 | 0.92 | HTR4 (0.41) | KDM4EBTKHTR4GRIN1GRIN2B | |
| SCHEMBL982770 | 0.91 | BTK (0.47) | KDM4EBTKHTR4CD38SMYD3 | |
| SCHEMBL981989 | 0.91 | BTK (0.47) | KDM4EBTKHTR4CD38SMYD3 | |
| SCHEMBL982971 | 0.91 | HTR4 (0.40) | KDM4EBTKMEN1KMT2AHTR4 | |
| SCHEMBL983576 | 0.91 | HTR4 (0.40) | KDM4EBTKMEN1KMT2AHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | KDM4E 1035/4885BTK 1977/4885MEN1 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.